Gotham Asset Management LLC Has $5.69 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Gotham Asset Management LLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 28.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,762 shares of the company's stock after selling 5,600 shares during the period. Gotham Asset Management LLC's holdings in IDEXX Laboratories were worth $5,690,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. United Capital Financial Advisors LLC raised its holdings in shares of IDEXX Laboratories by 0.9% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after purchasing an additional 22 shares in the last quarter. Cranbrook Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock valued at $158,000 after acquiring an additional 25 shares during the period. Gabelli Funds LLC raised its holdings in shares of IDEXX Laboratories by 5.3% during the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after acquiring an additional 25 shares during the period. Perigon Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after acquiring an additional 26 shares during the period. Finally, Summit Trail Advisors LLC raised its holdings in shares of IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after acquiring an additional 26 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 1.2%

IDEXX Laboratories stock traded up $6.11 during midday trading on Friday, hitting $518.10. 524,927 shares of the stock were exchanged, compared to its average volume of 648,919. The company has a fifty day simple moving average of $431.28 and a two-hundred day simple moving average of $431.42. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $545.43. The stock has a market capitalization of $41.67 billion, a PE ratio of 48.56, a P/E/G ratio of 3.41 and a beta of 1.52. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same quarter in the previous year, the firm posted $2.71 earnings per share. The business's revenue was up 3.6% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating on the stock in a research note on Monday, April 14th. StockNews.com upgraded shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Barclays upped their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Bank of America upped their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of "Moderate Buy" and an average target price of $524.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.